WO 2010/120253 Al

Total Page:16

File Type:pdf, Size:1020Kb

WO 2010/120253 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 21 October 2010 (21.10.2010) WO 2010/120253 Al (51) International Patent Classification: Tarcan Sokak No:5/1, Gayrettepe ISTANBUL 34349 A61K 31/704 (2006.01) A61K 31/5415 (2006.01) (TR). A61K 45/06 (2006.01) A61K 31/542 (2006.01) (74) Agent: KAYACAN, Vidan; Kirkkonaklar Mh. 327. Sk. A61P 19/00 (2006.01) No: 13/13, Qankaya ANKARA 06610 (TR). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/TR2009/000137 kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 4 November 2009 (04.1 1.2009) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 2009/03036 17 April 2009 (17.04.2009) TR SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (71) Applicant (for all designated States except US): TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. MUSTAFA NEVZAT ILAC SANAYII A.S. [TR/TR]; (84) Designated States (unless otherwise indicated, for every Pak Is Merkezi, Prof. Dr. Bϋlent Tarcan Sok. 5/1, 80290 kind of regional protection available): ARIPO (BW, GH, Gayrettepe, Istanbul (TR). GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (72) Inventors; and ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, (75) Inventors/Applicants (for US only): PISAK, Ibrahim TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Mustafa Iskender [TR/TR]; Pak Is Merkezi; Prof.Dr.Bϋ- ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, lent Tarcan Sokak No:5/1, Gayrettepe ISTANBUL 34349 MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, (TR). SELAMOGLU, Mehmet Levent [TR/TR]; Pak Is TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Merkezi; Prof.Dr.Bulent Tarcan Sokak No: 5/1, Gayrette ML, MR, NE, SN, TD, TG). pe ISTANBUL 34349 (TR). BINGOL, Semra [TR/TR]; Published: Pak Is Merkezi; Prof.Dr.Bulent Tarcan Sokak No:5/1, Gayrettepe ISTANBUL 34349 (TR). SERBETCIOGLU, — with international search report (Art. 21(3)) Marie Brunet [TR/TR]; Pak Is Merkezi; Prof.Dr.Bulent (54) Title: THIOCOLCHICOSIDE AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG COMBINATIONS (57) Abstract: This invention relates to pharmaceutical compositions and unit dosage forms containing in combination: the mus- cle relaxant thiocolchicoside or a salt of thereof or any therapeutically active stereoisomer thereof, substantially free of its other stereoisomers; a non-steroidal anti-inflammatory drug (NSAID). Thiocolchicoside and non-steroidal anti-inflammatory drug combinations This invention relates to pharmaceutical compositions and unit dosage forms containing in combination: i. the muscle relaxant thiocolchicoside or a salt of thereof or any therapeutically active stereoisomer therof, substantially free of its other stereoisomers; ii. a non-steroidal anti-inflammatory drug (NSAID). The pharmaceutical compositions are useful for the treatment of musculo-skelatal disorders and the treatment of pain and inflammation in mammalian organism, especially for the treatment of low back pain. Thiocolchicoside is a glycosulfurated analogue of colchicine and is a well known centrally acting muscle relaxant used in the treatment of musculo-skelatel disorders. Its chemical structure is shown in the Formula 1. Formula 1 The chemical name of thiocolchicoside is N-[3-(β-D-glucopyranosyloxy)-l,2- dimethoxy-10-(methylthio)-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide. The usual initial dose is 16 mg daily by oral administration in the form of capsules or tablets. It is also used for intramuscular administration in doses up to 8 mg per day or for topical application as cream, ointment, gel or aerosol. The non-steroidal anti-inflammatory drugs have been utilized in the treatment of pain and inflammation, as well as for a variety of disorders including rheumatoid and osteoarthritis. They vary widely in their chemical structure and biological profiles as analgesics, anti-inflammatory agents and antipyretic agents. They present a superior analgesic and anti-inflammatory activity compared to aspirin and paracetamol but also less side effects like gastrointestinal ulcerations and bleeding experienced with aspirin or hepatic toxicity with large doses of paracetamol. Centrally acting skeletal muscle relaxants are generally prescribed either as single agents or as components of combination products. Several commercial combinations of a muscle relaxant and aspirin have been approved by the US FDA and are marketed in the USA like carisoprodol + aspirin (Soma Compound, Meda Pharms), carisoprodol + aspirin + codeine (Soma Compound W/ Codeine), methocarbamol + aspirin (Methocarbarbamol and Aspirin, Ivax Pharms) and orphenadrine + aspirin + caffeine (Norgesic Forte, Graceway). However, few combinations of the muscle relaxant thiocolchicoside with NSAID have been described in the past and none of the descriptions includes the combinations disclosed in the present invention. French patent FR 2725134 Bl (Laboratoire Lederle), filed on 04.10.1994, describes a new combination comprising ibuprofen or a pharmaceutically acceptable salt thereof and thiocolchicoside or a pharmaceutically salt salt thereof in a weight ratio generally comprising between approximately 1:50 and approximately 1:200 for oral administration in a form of a capsule, a tablet or granules. European patent EP 0837684 Bl (Sanofi-Synthelabo), filed on 12.06.1996, describes a new combination comprising a diclofenac salt and thiocolchicoside with at least one pharmaceutically acceptable excipient and provided in a solid form which is stable over time. European patent EP 1992333 Al (Sanovel) describes a composition comprising flurbiprofen and an alpha-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist, in particular tizanidine and thiocolchicoside. The physicochemical compatibility of the injectable mixture of thiocolchicoside and other drugs frequently used in association, like anti-inflammatory drugs or vitamins, have been shown for a period of three hours at room temperature in solution (Farmaco. 2002 Nov; 57(1 1):925-30). The addition of thiocolchicoside to NSAID standard treatment has shown more effective results for the treatment of low back pain than the NSAID alone. In addition, the combination was well tolerated and produced no more adverse reactions than the NSAID alone (J Orthopaed Traumatol (2002) 3-103-108). The present invention describes new combinations of thiocolchicoside and NSAID in unit dosage form which is stable over time. The present invention relates to a combination of the muscle relaxant thiocolchicoside and its pharmaceutically acceptable salts with at least one non-steroidal anti¬ inflammatory drug and at least one pharmaceutically acceptable non-toxic carrier adapted for unit dose administration. The muscle relaxant for use in the pharmaceutical compositions and methods of use of the present invention is thiocolchicoside. The invention includes any pharmaceutically acceptable salt of thiocolchicoside and any therapeutically active stereoisomer of thiocolchicoside, substantially free of its other stereoisomers. The amount of thiocolchicoside useful in the practice of the present invention may vary from 4 mg to 16 mg depending on the mode of administration. The preferred amount of thiocolchicoside is selected from a range 4 to 8 mg per unit for parenteral administration. The preferred amount of thiocolchicoside is selected from a range 8 to 16 mg per unit for oral administration. The NSAID for use in the pharmaceutical compositions and methods of use of the present invention may be chosen from the group consisting of, but not limited to, the oxicams, the fenamic acid derivatives, the acetic acid derivatives, the propionic acid derivatives, the coxibs and other NSAIDs. They include all their pharmaceutically acceptable salts of thereof or therapeutically active stereoisomers therof, substantially free of their other stereoisomers. These compounds are well known to those skilled in art and described in various literature reference sources like the Merck Index for their chemical structures, pharmacological activities, side effects, normal dosage ranges, etc. The preferred oxicams for use in the present invention include, but are not limited to, lornoxicam, tenoxicam, meloxicam and piroxicam. The preferred fenamic acid derivatives for use in the present invention include, but are not limited to, mefenamic acid and etofenamate. The preferred acetic acid derivatives for use in the present invention include, but are not limited to, etodolac, acemetacin and indometacin. The preferred propionic acid derivatives for use in the present invention include, but are not limited to, tiaprofenic acid, naproxen and oxaprozin. The preferred coxibs for use in the present invention include, but are not limited to, celecoxib, rofecoxib, lumiracoxib and valdecoxib. The preferred other NSAID' s for use in the present invention include, but are not limited to, nimesulide. The preferred unit dose for the preferred compounds mentionned hereinabove are listed in Table 1. Compound Preferred
Recommended publications
  • WHO Pharmaceuticals Newsletters
    2021 WHO Pharmaceuticals No.1 NEWSLETTER The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicines WHO Vision for Medicines Safety and legal actions taken by regulatory authorities around No country left behind: the world. It also provides signals based on information worldwide pharmacovigilance for safer medicines, safer patients derived from the WHO global database of individual case safety reports, VigiBase. In addition, this edition of the Newsletter includes a The aim of the Newsletter is to disseminate regulatory summary of discussions and key recommendations of information on the safety of Advisory Committee on Safety of Medicinal Products pharmaceutical products, (ACSoMP) Seventeenth meeting. based on communications received from our network of national pharmacovigilance centres and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from: Safety and Vigilance: Medicines, EMP-HIS, World Health Organization, 1211 Geneva 27, Switzerland, Contents E -mail address: [email protected] This Newsletter is also available at: Regulatory matters http://www.who.int/medicines Safety of medicines Signal Feature WHO Pharmaceuticals Newsletter No. 1, 2021 ISBN 978-92-4-002136-5 (electronic version) ISBN 978-92-4-002137-2 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Etofenamate and Anastomoses of the Colon in Rats
    Turk J Med Sci ORIGINAL ARTICLE 2009; 39 (5): 713-718 © TÜBİTAK E-mail: [email protected] doi:10.3906/sag-0901-32 Aydın İNAN Etofenamate and anastomoses of the colon in rats Önder SÜRGİT Meral ŞEN Aim: Non-steroidal anti-inflammatory drugs have been used for many years due to their analgesic and anti-inflammatory properties. They have also been used for postoperative analgesia. We aimed Ayhan AKPINAR to study the effects of etofenamate, a non-steroidal anti-inflammatory drug, on the healing of colonic Mikdat BOZER anastomoses in rats. Materials and methods: Sprague-Dawley rats were used in this study. Resection and anastomosis were performed on the distal colon. The etofenamate group received 30 mg/kg etofenamate and the control group received 0.1 mL of 0.9% NaCl intramuscularly daily. Bursting pressures of anastomoses and hydroxyproline levels of perianastomotic tissues were determined on days 3 and 7. Results: Four deaths were observed in each group. Mean bursting pressures (etofenamate group, day 3: 50.50 ± 7.27 mmHg, day 7: 187.37 ± 12.20 mmHg; control group, day 3: 55.13 ± 5.94 mmHg, day 7: 202.12 ± 18.64 mmHg) and mean hydroxyproline levels (etofenamate group, day 3: 2.18 ± 0.17 Department of General Surgery, μg/mg tissue, day 7: 4.34 ± 0.79 μg/mg tissue; control group, day 3: 2.20 ± 0.12 μg/mg tissue, day 7: Faculty of Medicine, 5.07 ± 0.65 μg/mg tissue) in the etofenamate group were lower than those in the control group on Fatih University, both days 3 and 7.
    [Show full text]
  • Development of a Topical Anti- Inflammatory Flurbiprofen Gel
    UNIVERSIDADE DE LISBOA Faculdade de Farmácia DEVELOPMENT OF A TOPICAL ANTI- INFLAMMATORY FLURBIPROFEN GEL Dissertação elaborada para a obtenção do grau de Mestre em Engenharia Farmacêutica Lisboa 2016 Joana Raquel Baptista de Brito Martins Orientadores: Professora Doutora Helena Margarida Ribeiro e Doutora Sara Raposo UNIVERSIDADE DE LISBOA Faculdade de Farmácia DEVELOPMENT OF A TOPICAL ANTI- INFLAMMATORY FLURBIPROFEN GEL Dissertação elaborada para a obtenção do grau de Mestre em Engenharia Farmacêutica Lisboa 2016 Joana Raquel Baptista de Brito Martins Orientadores: Professora Doutora Helena Margarida Ribeiro e Doutora Sara Raposo i Abstract All over the years, anti-inflammatory therapy is being related to non-steroids anti-inflammatory drugs (NSAIDs). This therapeutic class has proved promising on the market once it decreases systemic adverse effects. In Portugal, there is actually 59 anti-inflammatory drugs for topical use allowed to be commercialized (Autorização de Introdução no Mercado – AIM) by Infarmed under the dosage form of gel. The main aim of this work was a topical non-steroid anti-inflammatory hydrogel development. There is no product with topical application, on the Portuguese market, with flurbiprofen. The patent describing Froben ® manufacturing, commercialized by Abbott, was used as a model. This product describes a formulation with 5% of flurbiprofen. It was developed drug solubility studies, polymer quantity and cutaneous promoters selection. For that, a Quality by Design (QbD) approach was used. The menthol and oleic acid were used as permeation enhancers because they are associated to permeability and dermic retention increase. After that, final formulations were developed, and the skin permeation and retention studied. The results were compared with the oleogel formulation described by the patent.
    [Show full text]
  • Principios Activos Fotosensibles
    PRINCIPIOS ACTIVOS FOTOSENSIBLES PROTEGE A TUS PRODUCTOS DE LA FOTODEGRADACIÓN PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen
    [Show full text]
  • Allergic and Photoallergic Contact Dermatitis to Topical Non-Steroidal Anti-Inflammatory Drugs: a Case Series from Turkey
    CONTACT DERMATITIS AND OCCUPATIONAL DERMATOSES ALLERGIC AND PHOTOALLERGIC CONTACT DERMATITIS TO TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: A CASE SERIES FROM TURKEY E Ozkaya (1) - A Kutlay (1) Istanbul University Istanbul Medical Faculty, Dermatology, Istanbul, Turkey (1) Background: Topical non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, mainly for soft tissue pain and injury. Allergic contact dermatitis (ACD) and photoallergic contact dermatitis (PACD) from topical NSAIDs have been reported with an increasing incidence. Ketoprofen seems to be the major culprit drug, followed by etofenamate and bufexamac in many European countries. There are only limited data on this subject in Turkey. Observation: Out of 2375 consecutively patch tested patients in our clinic between 1996 and 2017, 13 patients (7 male, 6 female, age range: 21-81, median: 56 years) (0.5%) were diagnosed with topical NSAID-induced ACD/PACD. Patients were patch tested (n=13) and photopatch tested (n=4) with the suspected topical preparations as is, and with the active (n=4) and inactive ingredients, when available, in addition to the European baseline series. Etofenamate (tested in a dilution series of 1%-5%-10% in petrolatum and aqua) was the leading culprit drug in 8 patients (62%), followed by ketoprofen (n=2), diclofenac (n=2), and diethylamine salicylate & naproxen (n=1). The main diagnosis was ACD whereas PACD was diagnosed in 2 patients from etofenamate and ketoprofen. Concomitant positive reaction were observed with inactive ingredients such as benzyl alcohol in etofenamate, and neroli oil in ketoprofen preparations, respectively. Cross-reaction to fragrances (fragrance mix I, balsam of Peru, cinnamic alcohol/aldehyde) was present in both patients with ketoprofen allergy.
    [Show full text]
  • Preemptive Use of Etofenamate in Laparoscopic Cholecystectomy: a Randomized, Placebo-Controlled, Double-Blind Study
    Original Article Preemptive Use of Etofenamate in Laparoscopic Cholecystectomy: A Randomized, Placebo-Controlled, Double-Blind Study. Meral Şen1, Aydın İnan1, Hüseyin Sert2, Ayhan Akpınar1, Cenap Dener1 Fatih University, Medical School, ABSTRACT Departments of General Surgery1 and Anesthesiology2, Ankara, Turkey Aim: To investigate the preemptive effect of etofenomate on postoperative pain and emesis in the first 24 hours after elective Eur J Gen Med 2010;7(1): 50-55 laparoscopic cholecystectomy. Method: Patients were randomly assigned to two groups each consisting of 60 patients. Group A was received 1g (2 ml) etofenomate intramuscularly, group B was received 0.9% saline intramuscularly one hour before surgery. All patients were administered meperidine HCl in the patient –controlled analgesia (PCA) intravenous mode in order to treat postoperative pain. Pain intensity was assessed on visual analog scales (VAS) at four times; 1 hour, 6 hours, 12 hours and 24 hours. The total meperidine HCl consumptions, VAS scores and antiemetic requirements were recorded and comparisons among the two groups were evaluated. Result: The mean total meperidine HCl consumptions within first 6 and 24 hours of the group A were significantly less than the group B. The VAS scores at 1 and 6 hours in the group A were significantly lower than that in the group B. There was no significant difference in the postoperative antiemetic requirement among two groups. Conclusion: Preemptive use of etofenamate reduces pain intensity and meperidine HCl requirement, but it doesn’t
    [Show full text]
  • Myofascial Pain Syndrome: a Treatment Review Mehul J
    Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Anesthesiology and Critical Care Medicine Faculty Anesthesiology and Critical Care Medicine Publications 6-2013 Myofascial pain syndrome: A treatment review Mehul J. Desai George Washington University Vikramjeet Saini Shawnjeet Saini Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_anesth_facpubs Part of the Anesthesia and Analgesia Commons Recommended Citation Desai, M. J., Saini, V., & Saini, S. (2013). Myofascial Pain Syndrome: A Treatment Review. Pain and Therapy, 2(1), 21–36. This Journal Article is brought to you for free and open access by the Anesthesiology and Critical Care Medicine at Health Sciences Research Commons. It has been accepted for inclusion in Anesthesiology and Critical Care Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [email protected]. Pain Ther (2013) 2:21–36 DOI 10.1007/s40122-013-0006-y REVIEW Myofascial Pain Syndrome: A Treatment Review Mehul J. Desai • Vikramjeet Saini • Shawnjeet Saini To view enhanced content go to www.paintherapy-open.com Received: September 27, 2012 / Published online: February 12, 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com ABSTRACT and nonpharmacologic treatments, the authors aim to provide clinicians with a more Myofascial pain syndrome (MPS) is defined as comprehensive knowledge of the interventions pain that originates from myofascial trigger for myofascial pain. points in skeletal muscle. It is prevalent in regional musculoskeletal pain syndromes, either alone or in combination with other pain Keywords: Analgesics; Anticonvulsants; generators. The appropriate evaluation and Muscle relaxants; Myofascial pain; management of myofascial pain is an important Nonpharmacological treatment; Pain; part of musculoskeletal rehabilitation, and Treatment regional axial and limb pain syndromes.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • [Product Name] 500 Mg + 2 Mg Tablet Paracetamol + Thiocolchicoside
    Package leaflet: Information for the user [Product name] 500 mg + 2 mg Tablet Paracetamol + Thiocolchicoside This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What [Product name] is and what it is used for 2. What you need to know before you take [Product name] 3. How to take [Product name] 4. Possible side effects 5. How to store [Product name] 6. Contents of the pack and other information 1. What [Product name] is and what it is used for This medicine is a muscle relaxant. It is used in adults and adolescents from 16 years old as an adjunctive treatment for painful muscle contractions. It is used for spine-related acute episodes. 2. What you need to know before you take [Product name] Do not take [Product name]: - if you are allergic to paracetamol, thiocolchicoside or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • Innovations from 'Down-Under': a Focus on Prescription to Non-Prescription Medicine Reclassification in New Zealand and Australia
    ORIGINAL ARTICLE SelfCare 2012;3(5):88-107 Advancing the study&understanding of self-care INNOVATIONS FROM ‘DOWN-UNDER’: A FOCUS ON PRESCRIPTION TO NON-PRESCRIPTION MEDICINE RECLASSIFICATION IN NEW ZEALAND AND AUSTRALIA NATALIE GAULD*, FIONA KELLY**, LYNNE EMMERTON†, LINDA BRYANT††, STEPHEN BUETOW‡ * PhD Candidate, Department of General Practice and Primary Health Care, University of Auckland, New Zealand **Honorary Senior Lecturer, School of Pharmacy, University of Auckland, New Zealand †Associate Professor, School of Pharmacy, Curtin Health Innovation Research Institute, Perth, Western Australia †† Honorary Lecturer, Department of General Practice and Primary Health Care, University of Auckland, New Zealand ‡Associate Professor, Department of General Practice and Primary Health Care, University of Auckland, New Zealand ABSTRACT BACKGROUND: Australia and New Zealand (NZ) contribute to the international trend of medicines reclassification from prescription to non-prescription availability (switch). Both countries have been acknowledged as being as advanced or even more so than the United Kingdom (UK) in availability of medicines without prescription, despite not making some of the recent innovative UK switches. OBJECTIVE: To derive a measure of progressiveness in switch; to compare the progressiveness of switch between NZ and Australia; and to compare NZ and Australia switch activity with the UK. METHODS: Records of medicines classification meetings in Australia and NZ from 2000 to 2011 were analysed with respect to all switch considerations (whether approved or not approved). Switches in Australia and NZ were compared with those in the UK. A new measure, ‘innovative switches’, was developed to provide a useful measure of switch progress. RESULTS: Australia demonstrated ‘switch innovation’ in the early 2000s, including the ‘first-in-world’ switch of orlistat, but has slowed down since.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]